AstraZeneca

AZNleader

AstraZeneca is a global biopharmaceutical company with a market-leading oncology portfolio and strong positions in cardiovascular, respiratory, and rare disease therapies.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($49.8B)

静态数据（加载实时财务…）

Oncology (40%)

BioPharmaceuticals (38%)

Rare Disease (Alexion) (17%)

Other (5%)

业务板块构成与主要客户

产品详情

Oncology Portfolio40%

Tagrisso, Imfinzi, Enhertu, and Lynparza cancer treatments

Cardiovascular/Renal/Metabolic22%

Farxiga, Brilinta, and Lokelma for heart and kidney disease

Respiratory & Immunology20%

Symbicort, Fasenra, and Tezspire for asthma and COPD

Rare Disease (Alexion)18%

Soliris, Ultomiris for complement-mediated diseases

供应链关系

竞争对手

Merck & Co.

Oncology immunotherapy

影响: High — PD-L1 vs PD-1 competition

Pfizer Inc.

Respiratory and oncology

影响: Medium — multiple overlapping areas

合作伙伴

Eli Lilly and Company

Enhertu co-development (with Daiichi Sankyo)

影响: N/A — Daiichi partner, Lilly rival

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 AstraZeneca 的 AI 供应链分析。

企业信息

总部

Cambridge, United Kingdom

成立时间

1999

员工人数

89,000+

官网

astrazeneca.com

行业概况 — 제약 / 바이오

行业新闻